<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01077180</url>
  </required_header>
  <id_info>
    <org_study_id>360005-001</org_study_id>
    <nct_id>NCT01077180</nct_id>
  </id_info>
  <brief_title>Rheos Feasibility Trial</brief_title>
  <official_title>Rheos Feasibility Trial- A Study of Baroreflex Hypertension TherapyTM in Refractory Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CVRx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CVRx, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Rheos Feasibility Trial is designed to assess safety, device performance, and protocol&#xD;
      parameters of the CVRx Rheos Baroreflex Therapy in patients with severe hypertension that are&#xD;
      refractory to full drug therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rheos Feasibility Study</measure>
    <time_frame>13 months</time_frame>
    <description>To summarize the efficacy of the Rheos System by estimating the reduction of systolic blood pressure associated with activation of the Rheos System at 4 and 13 months post implant when compared to baseline (1-month post implant).&#xD;
To describe the safety of the Rheos System by summarizing all system related adverse events and estimating the serious sytem related event-free rate through 4 and 13 months post-implant.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Rheos Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical Management</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantation of the Rheos System</intervention_name>
    <description>Open label</description>
    <arm_group_label>Rheos Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care medical management</intervention_name>
    <description>Patients will continue with medical therapy for standard of care of their hypertension.</description>
    <arm_group_label>Medical Management</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be at least 21 years of age.&#xD;
&#xD;
          2. Have been assessed to have bilateral carotid bifurcations located at or below C3-C4.&#xD;
&#xD;
          3. Have an office cuff systolic blood pressure greater than or equal to 160 mmHg and a&#xD;
             24-hour ambulatory systolic blood pressure greater than or equal to 150 mmHg despite&#xD;
             at least one month of full therapy with at least three (3) anti-hypertensive&#xD;
             medications, of which at least one (1) must be a diuretic.&#xD;
&#xD;
          4. Must be certified by the investigator hypertension specialist as compliant with taking&#xD;
             full doses of medication.&#xD;
&#xD;
          5. Have signed a CVRx approved informed consent for participation in this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have been diagnosed with:&#xD;
&#xD;
               -  Baroreflex failure&#xD;
&#xD;
               -  Cardiac bradyarrhythmias&#xD;
&#xD;
               -  Chronic atrial fibrillation&#xD;
&#xD;
          2. Had a heart transplant&#xD;
&#xD;
          3. Have carotid atherosclerosis producing a 50% or greater reduction in linear diameter&#xD;
             as determined by ultrasound or angiographic evaluation as determined within six months&#xD;
             of enrollment in the trial.&#xD;
&#xD;
          4. Have Grade C ulcerative plaques in the carotid artery as determined by ultrasound or&#xD;
             angiographic evaluation.&#xD;
&#xD;
          5. Have prior surgery or radiation in either carotid sinus region.&#xD;
&#xD;
          6. Currently have implanted electrical medical devices such as cardiac pacing,&#xD;
             defibrillation or neurologic stimulation systems.&#xD;
&#xD;
          7. Are pregnant or contemplating pregnancy during the 13-month follow-up period.&#xD;
&#xD;
          8. Currently undergoing dialysis.&#xD;
&#xD;
          9. Have hypertension secondary to a treatable cause.&#xD;
&#xD;
         10. Have clinically significant cardiac valvular disease.&#xD;
&#xD;
         11. Are unable or unwilling to fulfill the protocol medication compliance and follow-up&#xD;
             requirements.&#xD;
&#xD;
         12. Are unlikely to survive the protocol follow-up period.&#xD;
&#xD;
         13. Are enrolled in another concurrent clinical trial.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>February 25, 2010</study_first_submitted>
  <study_first_submitted_qc>February 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2010</study_first_posted>
  <last_update_submitted>June 28, 2019</last_update_submitted>
  <last_update_submitted_qc>June 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

